JP2023528039A - 改変環状ポリヌクレオチド - Google Patents

改変環状ポリヌクレオチド Download PDF

Info

Publication number
JP2023528039A
JP2023528039A JP2022573508A JP2022573508A JP2023528039A JP 2023528039 A JP2023528039 A JP 2023528039A JP 2022573508 A JP2022573508 A JP 2022573508A JP 2022573508 A JP2022573508 A JP 2022573508A JP 2023528039 A JP2023528039 A JP 2023528039A
Authority
JP
Japan
Prior art keywords
nucleotides
polynucleotide
rna
modified
target rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528039A5 (enExample
Inventor
パッカード，トーマス
サバ，イアニス
ペラレス，ロベルト
サリバン，リチャード
Original Assignee
シェイプ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェイプ セラピューティクス インコーポレイテッド filed Critical シェイプ セラピューティクス インコーポレイテッド
Publication of JP2023528039A publication Critical patent/JP2023528039A/ja
Publication of JP2023528039A5 publication Critical patent/JP2023528039A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022573508A 2020-05-26 2021-05-26 改変環状ポリヌクレオチド Pending JP2023528039A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029996P 2020-05-26 2020-05-26
US63/029,996 2020-05-26
US202063112488P 2020-11-11 2020-11-11
US63/112,488 2020-11-11
US202063119902P 2020-12-01 2020-12-01
US63/119,902 2020-12-01
US202163178056P 2021-04-22 2021-04-22
US63/178,056 2021-04-22
PCT/US2021/034301 WO2021242889A1 (en) 2020-05-26 2021-05-26 Engineered circular polynucleotides

Publications (2)

Publication Number Publication Date
JP2023528039A true JP2023528039A (ja) 2023-07-03
JP2023528039A5 JP2023528039A5 (enExample) 2024-05-09

Family

ID=76523478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573508A Pending JP2023528039A (ja) 2020-05-26 2021-05-26 改変環状ポリヌクレオチド

Country Status (4)

Country Link
US (1) US20230174977A1 (enExample)
EP (1) EP4158017A1 (enExample)
JP (1) JP2023528039A (enExample)
WO (1) WO2021242889A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
CA3035293A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CN114269919B (zh) * 2019-07-12 2023-08-18 北京大学 采用工程化rna利用内源adar进行靶向的rna编辑
AU2020395113A1 (en) 2019-12-02 2022-06-09 Shape Therapeutics Inc. Therapeutic editing
US20230036370A1 (en) * 2019-12-02 2023-02-02 The Regents Of The University Of California Engineering circular guide rnas
WO2022150974A1 (en) * 2021-01-12 2022-07-21 Peking University Targeted rna editing by leveraging endogenous adar using engineered rnas
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
CN120322556A (zh) 2022-12-09 2025-07-15 ProQR治疗上市公司Ⅱ 用于治疗心血管疾病的反义寡核苷酸
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
CN121002181A (zh) 2023-03-27 2025-11-21 ProQR治疗上市公司Ⅱ 用于治疗肝脏疾病的反义寡核苷酸
WO2024235293A1 (zh) * 2023-05-17 2024-11-21 中国科学院遗传与发育生物学研究所 基于环状rna的引导编辑系统
AR132964A1 (es) 2023-06-16 2025-08-13 Proqr Therapeutics Ii Bv Oligonucleótidos antisentido para el tratamiento de enfermedades neurodegenerativas
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025137637A2 (en) * 2023-12-21 2025-06-26 Shape Therapeutics Inc. Wobble base pairs for improving specificity of rna editing
WO2025207635A1 (en) * 2024-03-25 2025-10-02 University Of Wyoming Compositions and methods for stabilizing a biological material or biologically-derived material
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082644A1 (en) * 2012-11-30 2014-06-05 WULFF, Peter, Samuel Circular rna for inhibition of microrna
JP2017537618A (ja) * 2014-12-17 2017-12-21 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップＰｒｏＱＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＩＩ Ｂ．Ｖ． 標的化ｒｎａ編集
WO2020051555A1 (en) * 2018-09-06 2020-03-12 The Regents Of The University Of California Rna and dna base editing via engneered adar recruitment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3475424A1 (en) * 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018237372A1 (en) * 2017-06-23 2018-12-27 Cornell University RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT
CN114269919B (zh) * 2019-07-12 2023-08-18 北京大学 采用工程化rna利用内源adar进行靶向的rna编辑
US20230036370A1 (en) * 2019-12-02 2023-02-02 The Regents Of The University Of California Engineering circular guide rnas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082644A1 (en) * 2012-11-30 2014-06-05 WULFF, Peter, Samuel Circular rna for inhibition of microrna
JP2017537618A (ja) * 2014-12-17 2017-12-21 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップＰｒｏＱＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＩＩ Ｂ．Ｖ． 標的化ｒｎａ編集
WO2020051555A1 (en) * 2018-09-06 2020-03-12 The Regents Of The University Of California Rna and dna base editing via engneered adar recruitment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE BIOTECHNOLOGY, vol. 37, no. 9, JPN6025014886, 2019, pages 1059 - 1069, ISSN: 0005572340 *

Also Published As

Publication number Publication date
WO2021242889A1 (en) 2021-12-02
EP4158017A1 (en) 2023-04-05
US20230174977A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
US20230174977A1 (en) Engineered circular polynucleotides
US12123002B2 (en) Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US20230193279A1 (en) Compositions and Methods for Modifying Target RNAs
JP7720623B6 (ja) 遺伝子操作されたａｄａｒのリクルートを介したｒｎａ及びｄｎａ塩基の編集
JP2023523237A (ja) ｓｎＲＮＡ構成要素を使用する組成物及び方法
US20230399635A1 (en) RNA-Editing Compositions and Methods of Use
CN119876138A (zh) 调节性多核苷酸
JP2023513188A (ja) 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤
JP2025528393A (ja) Ｒｎａペイロードの転写を増やすための操作された構築物
CN116547384A (zh) 用于修饰靶rna的组合物和方法
CN116568804A (zh) 工程化环状多核苷酸
EP3690046A2 (en) Composition for treatment of hemophilia, comprising crispr/cas system having coagulation factor viii gene inversion correction potential
JP2024506869A (ja) Ｎｌｒｐ３発現の異常に関連する疾患または障害を治療するためのｍｉｒｎａ－４８５阻害剤の使用
CN116648508A (zh) Rna编辑组合物和使用方法
CN117980480A (zh) 工程化引导rna和多核苷酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251014